The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Ramucirumab (RAM) plus FOLFOX as front-line therapy (Rx) for advanced gastric or esophageal adenocarcinoma (GE-AC): Randomized, double-blind, multicenter phase 2 trial.
Harry H. Yoon
Research Funding - Lilly
Johanna C. Bendell
No relevant relationships to disclose
Fadi S. Braiteh
No relevant relationships to disclose
Irfan Firdaus
No relevant relationships to disclose
Philip Agop Philip
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Celgene; Lilly; Sanofi
Research Funding - Bayer; Bristol-Myers Squibb; Incyte; Lilly; Sanofi
Allen Lee Cohn
Consultant or Advisory Role - Lilly
Nancy Lewis
No relevant relationships to disclose
Daniel M. Anderson
No relevant relationships to disclose
Edward Arrowsmith
No relevant relationships to disclose
Jonathan D. Schwartz
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Yihuan Xu
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Minori Koshiji
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Steven R. Alberts
No relevant relationships to disclose
Zev A. Wainberg
Research Funding - Lilly